West Pharmaceutical Services, Inc. Website

West Pharmaceutical Services, Inc.

NYSE-WST

Basic

  • Market Cap

    $23.16B

  • EV

    $22.86B

  • Shares Out

    72.84M

  • Revenue

    $2,928.6M

  • Employees

    10,600

Margins

  • Gross

    37.18%

  • EBITDA

    27.64%

  • Operating

    22.82%

  • Pre-Tax

    23.35%

  • Net

    19.42%

  • FCF

    13.18%

Returns (5Yr Avg)

  • ROA

    16.17%

  • ROTA

    23.38%

  • ROE

    23.08%

  • ROCE

    23.36%

  • ROIC

    23.51%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $395.29

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $601.8M

  • Net Debt

    -$295.2M

  • Debt/Equity

    0.11

  • EBIT/Interest

    79.56

Growth (CAGR)

  • Rev 3Yr

    7.98%

  • Rev 5Yr

    10.91%

  • Rev 10Yr

    7.85%

  • Dil EPS 3Yr

    10.85%

  • Dil EPS 5Yr

    21.28%

  • Dil EPS 10Yr

    17.58%

  • Rev Fwd 2Yr

    5.43%

  • EBITDA Fwd 2Yr

    9.16%

  • EPS Fwd 2Yr

    5.71%

  • EPS LT Growth Est

    9.84%

Dividends

  • Yield

  • Payout

    10.16%

  • DPS

    $0.78

  • DPS Growth 3Yr

    5.73%

  • DPS Growth 5Yr

    6.1%

  • DPS Growth 10Yr

    7.18%

  • DPS Growth Fwd 2Yr

    18.84%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

LTM

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Total Revenues

1,839.9

2,146.9

2,831.6

2,886.9

2,949.8

2,928.6

Total Revenues % Chg.

7.1%

16.7%

31.9%

2%

2.2%

1.6%

Cost of Goods Sold, Total

1,234.2

1,379.1

1,653.9

1,750.7

1,819.8

1,839.7

Gross Profit

605.7

767.8

1,177.7

1,136.2

1,130

1,088.9

Selling General & Admin Expenses, Total

272.8

300.8

356.3

316

354.1

354.8

Stock-Based Compensation

R&D Expenses

38.9

46.9

52.8

58.5

68.4

68.9

Other Operating Expenses

-2

-2.5

-4.3

-5.6

-3

-3.1

Other Operating Expenses, Total

309.7

345.2

404.8

368.9

419.5

420.6

Operating Income

296

422.6

772.9

767.3

710.5

668.3

Interest Expense, Total

-8.5

-8.2

-8.2

-7.9

-9

-8.4

Interest And Investment Income

3.8

1.4

1

5.1

28

29.4

Net Interest Expenses

-4.7

-6.8

-7.2

-2.8

19

21

Income (Loss) On Equity Invest.

8.9

17.4

20.1

20.7

17.7

16.3

Currency Exchange Gains (Loss)

4.6

1.5

1.4

4.1

-9.4

-9.7

EBT, Excl. Unusual Items

304.8

434.7

787.2

789.3

737.8

695.9

Restructuring Charges

-3

-4.6

-2.2

-23.8

2

2

Gain (Loss) On Sale Of Investments

-2.5

-4.3

-3.5

-4.3

-4.3

Gain (Loss) On Sale Of Assets

-11.6

-2.2

Asset Writedown

-2.7

-7.7

-8.4

-6.2

-9.6

-8.3

Legal Settlements

4.7

3.8

3.8

Other Unusual Items

-3.1

-1.2

-3.3

-55.2

-2.4

-3.1

EBT, Incl. Unusual Items

300.7

418.7

769

700.6

715.7

683.8

Income Tax Expense

59

72.5

107.2

114.7

122.3

115.1

Earnings From Continuing Operations

241.7

346.2

661.8

585.9

593.4

568.7

Net Income

241.7

346.2

661.8

585.9

593.4

568.7

Net Income to Common Incl Extra Items

241.7

346.2

661.8

585.9

593.4

568.7

Net Income to Common Excl. Extra Items

241.7

346.2

661.8

585.9

593.4

568.7

Total Shares Outstanding

74.1

74

74.2

74.1

73.5

73

Weighted Avg. Shares Outstanding

74

73.9

74.4

74.4

74.3

74.1

Weighted Avg. Shares Outstanding Dil

75.4

75.8

76.3

75.8

75.3

75

EPS

3.3

4.7

8.9

7.9

8

7.7

EPS Diluted

3.2

4.6

8.7

7.7

7.9

7.6

EBITDA

399.4

531.7

895.2

887.9

847.8

809.6

Effective Tax Rate

19.6%

17.3%

13.9%

16.4%

17.1%

16.8%